GlassScriptPhysician profile
Julius L Leary
NPI 1053377986
$327.07
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $53.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $108.80 | 2019 | |
| Intuitive Surgical, INC. | $32.29 | 2020 | |
| Hologic Sales and Service, LLC | $27.72 | 2019 | |
| Abbvie INC. | $26.54 | 2019 | |
| Amag Pharmaceuticals, INC. | $26.06 | 2019 | |
| Amgen INC. | $23.17 | 2019 | |
| Therapeuticsmd, INC. | $21.61 | 2020 | |
| Merck Sharp & Dohme LLC | $14.10 | 2019 | |
| Astellas Pharma US INC | $12.84 | 2019 | |
| Avion Pharmaceuticals | $11.37 | 2019 | |
| Pfizer INC. | $11.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Leary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.